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Background. Although herbal medicines are used by patients with cancer in multiple oncology care settings, the magnitude of
herbal medicine use in this context remains unclear. The purpose of this review was to establish the prevalence of herbal medicine
use among patients with cancer, across various geographical settings and patient characteristics (age and gender categories).
Methods. Electronic databases that were searched for data published, from January 2000 to January 2020, were Medline (PubMed),
Google Scholar, Embase, and African Index Medicus. Eligible studies reporting prevalence estimates of herbal medicine use
amongst cancer patients were pooled using random-eﬀects meta-analyses. Studies were grouped by World Bank region and
income groups. Subgroup and meta-regression analyses were performed to explore source of heterogeneity. Results. In total, 155
studies with data for 809,065 participants (53.95% female) met the inclusion criteria. Overall, the pooled prevalence of the use of
herbal medicine among patients with cancer was 22% (95% conﬁdence interval (CI): 18%–25%), with the highest prevalence
estimates for Africa (40%, 95% CI: 23%–58%) and Asia (28%, 95% CI: 21%–35%). The pooled prevalence estimate was higher
across low- and middle-income countries (32%, 95% CI: 23%–42%) and lower across high-income countries (17%, 95% CI: 14%–
21%). Higher pooled prevalence estimates were found for adult patients with cancer (22%, 95% CI: 19%–26%) compared with
children with cancer (18%, 95% CI: 11%–27%) and for female patients (27%, 95% CI: 19%–35%) compared with males (17%, 95%
CI: 1%–47%). Conclusion. Herbal medicine is used by a large percentage of patients with cancer use. The ﬁndings of this review
highlight the need for herbal medicine to be integrated in cancer care.

1. Introduction
Cancer is a major global health problem. In 2018, there were
an estimated 9.6 million cancer fatalities and 18.1 million
newly diagnosed cases [1]. Current trends indicate that the
previously predicted increase to 20 million new cases by
2025 is likely to be surpassed [2]. The overall implications of
this high rate of new cases of cancer include increased health,
economic, and social costs, which will continue to put a

burden on the limited resources and weak healthcare systems in poor countries. As a result, herbal (traditional)
medicines use in cancer care may be increased in those
countries.
Herbal medicine use associated with cancer, including in
multiple oncology care settings, remains uncontested [3].
Previous studies have indicated that herbal medicine is the
commonest form of complementary and alternative medicine (CAM) used by patients with cancer, with increasing

2
use following a cancer diagnosis [4–12]. Furthermore, advances in conventional cancer care have not deterred patients with cancer from using herbal medicines for
numerous reasons, including patient- or disease-related
factors, cultural and historical factors, geographical or topological factors, and healthcare or system-related factors
[11, 13–21].
Several studies have identiﬁed and documented the
clinical (cancer disease) and individual (demographic)
factors associated with the usage of herbal medicine in
cancer. Numerous factors have been positively correlated
with herbal medicine use in cancer, such as young age, high
education level, high-income level, ethnicity, female gender,
cancer diagnosis, longer survival period since cancer diagnosis, receiving single or multiple cancer chemotherapies,
being married, completion of conventional cancer treatment, having certain cancer symptoms, cancer metastasis,
and belonging to speciﬁc social groups [22–27]. However,
old age, being a child, having cancer comorbidities, place of
residence, and the experience of chemotherapeutic side
eﬀects are negatively associated with herbal medicine use in
cancer [16, 26, 28].
Some herbal medicines possess compounds that are
pharmacologically active against cancer cells, and preclinical
studies have consistently shown that numerous herbal
medicines or herbs have antiapoptotic, anti-inﬂammatory,
cell regenerative, and antioxidant eﬀects on cancer cells.
However, the clinical evidence concerning the eﬃcacy of most
herbal medicines or speciﬁc herbs used in cancer is largely
inconclusive [29, 30]. Clinical studies have reported that the
use of herbal medicines in cancer lowered the mortality rate
hazard ratio of patients with lung cancer (thereby increasing
survival), improved patients’ quality of life through reducing
cancer symptoms and conventional drug side eﬀects (e.g.,
nausea and vomiting), and had chemopreventive activity
against certain cancers [17, 19, 31, 32].
Conversely, observational studies have indicated that
concomitant herbal medicines use with antineoplastic drugs
may result in drug to herb interaction (at all pharmacokinetic
and pharmacodynamics levels) and adverse side eﬀects or
events [9, 31, 33, 34]. Adverse side eﬀects or events range from
minor side eﬀects (e.g., gastrointestinal distress and allergy) to
severe organ failure (e.g., hepatotoxicity, nephrotoxicity, bone
marrow suppression, and respiratory and cardiac failure)
[31, 32, 35–37]. Importantly, the release of antioxidants by
herbal medicines is thought to reduce the oxidizing free
radicals created by radiotherapy and chemotherapeutic agents
against cancer cells, potentially reducing the eﬀectiveness of
conventional cancer treatment [24, 38]. Similarly, herbs
commonly used in cancer such as St. John’s wort and grape
juice induce cytochrome isoenzymes (especially CYP3A4),
which metabolize most conventional anticancer agents,
thereby reducing the eﬃcacy of targeted therapies such as
tyrosine kinase inhibitors and anticancer hormonal therapies
[31, 32, 38]. St. John’s wort, speciﬁcally, was found to reduce
the levels of plasma irinotecan, docetaxel, and imatinib
mesylate antichemotherapeutic agents’ concentrations [31].
Additionally, other herbs commonly used in cancer have been
found to cause bleeding tendencies following surgery (e.g.,
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ginkgo, garlic), hypoglycemia (e.g., ginseng), and hepatotoxicity (e.g., kava) and possess carcinogenic or negative
tumor moderating eﬀects [4, 35, 39]. In addition, heavy metal
contamination in some herbal medicines may alter the
pharmacokinetic proﬁle of commonly used conventional
cancer treatments [24, 38, 40].
Despite the widespread herbal medicines use among
cancer patients, associated factors, and potential beneﬁts and
risks, the overall pooled prevalence of the use of herbal
medicines among patients with cancer remains unclear.
Previous systematic reviews focused on cancer used qualitative (narrative synthesis) designs and focused on synthesizing primary data on the use of CAM treatment
modalities in general [41–47]. Therefore, we conducted a
meta-analysis to explore the prevalence of the use of herbal
medicine among patients with cancer across various geographical settings and patient characteristics and synthesized
the literature on commonly used herbs in cancer. Understanding the prevalence of herbal medicine use by patients
with cancer may help inform and guide healthcare policies
geared toward integrating herbal medicines use in cancer
care. Ultimately, this will help to improve outcomes for
patients with cancer, develop wider public health (community) policies around herbal medicine legislation, and
promote investment in education and research about herbal
medicines used in cancer.

2. Methods
2.1. Protocol Registration. PROSPERO guidelines were used
to develop this study protocol. The study protocol was
subsequently registered with the open source foundation
(doi: 10.31730/osf.io/cbtpy). The Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines are used to report this review’ ﬁndings (https://
www.prisma-statement.org, Supplementary Table 1).
2.2. Eligibility Criteria. We synthesized hospital- and population-based studies that reported the prevalence of the use
of herbal medicines among patients with cancer (Table 1).
2.3. Information Sources and Search Strategy. We searched
PubMed, Google Scholar, Embase, and African Index
Medicus for articles published from January 2000 to January
2020. The key search terms words that were used to guide the
search included the following: “Cancer” OR “Neoplasm” OR
“Tumo ∗ ” OR “Malignancy” AND “Herbs” OR “Herbal
medicine” OR “Herbal material” OR “Herbal preparation”
AND “Prevalence” OR “Use” OR “Proportion” OR
“Percent ∗ ” AND “Observational studies” OR “Cohort” OR
“Cross-sectional ∗ ” OR “Survey” OR “Cohort” (Supplementary Table 2). In addition, we manually skimmed the
references of published review articles and primary studies
to obtain any further eligible studies.
2.4. Data Extraction: Selection and Coding. After obtaining
relevant studies (A.J.B), two authors (P.P.N and A.M.S)
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Table 1: Inclusion and exclusion criteria for included studies.

Participants
Outcomes

Study design

Ethical
approval
Language

Inclusion criteria
Female and male participants of all ages suﬀering from cancer using herbal
medicine(s) with or without any other CAM remedy(s) or conventional remedy(s).
Prevalence of herbal medicine use (either reported or self-reported)
Herbs commonly used by patients with cancer
Cohort studies
Cross-sectional studies
Studies that were approved by an ethical review body or committee and
participants consented to participate.
Published in the English language

Exclusion criteria
Cancer survivors (recovered)
Prevalence not reported
Expert reviews
Case-control studies
Policy reports
Case studies
Studies with aggregated CAM
data
Lack of ethical approval and
participant consent
Published in any other language

pooled prevalence of herbal medicine use among patients
with cancer based on subgroup and meta-regression analyses [52, 53]. Modifying variables included the following: (i)
year of publication (before or after 2010), (ii) study focus
(herbal medicine alone vs. herbal medicine with other
CAM), (iii) data collection method (researcher-administered vs. self-administered vs. document or record reviews),
(iv) country income level (low and middle vs. high income),
(v) study setting (hospital vs. community), (vi) study population (adults vs. children), (vii) cancer type (breast vs.
prostate vs. hematological vs. others), (viii) region (continent), (ix) World Bank subregion, (x) study design (crosssectional vs. cohort), and (xi) study country. We evaluated
publication bias by inspecting the funnel plot for asymmetry
and conﬁrmed it using Egger’s regression test [54]. We also
reported the weighted pooled prevalence estimates and their
95% CIs. Data related to herbs used by patients with cancer
were summarized and described.

screened the identiﬁed articles’ abstracts and titles and
determined their eligibility for inclusion in this review,
independently. Two authors (J.B.A and A.M.S) independently extracted the data using a standard data extraction
form or tool created in Microsoft Excel 2016. Before data
were extracted, the data extraction tool was pilot tested with
10 studies. Following the ﬁndings of the pilot test, improvements to the data extraction tool were made after
reaching consensus with all reviewers. The extracted data
included the following: (i) methodological or study characteristics, (ii) herbal medicine deﬁnitions or terms used,
(iii) the focus of study (herbal medicine only or with other
CAM modalities), (iii) use of conventional treatment, (iv)
gender distribution, (v) participants’ average age, (vi) sample
size, (vii) proportion or frequency of herbal medicine use,
(viii) herbs used in cancer, and (ix) conclusions. Countries
were categorized by continent or world regions and
according to World Bank economic indicators (Supplementary Table 3). The authors were able to resolve disagreements during data extraction through consensus.

3. Results

2.5. Risk of Bias Assessment. Using the risk of bias of nonrandomized studies (RoBINS) tool, three authors (J.B.A,
A.M.S, and P.P.N) independently assessed and reported the
risk of bias in selected studies [48–50]. The risk of bias was
categorized as high, moderate (unclear), and low across the
various categories of bias (participation bias, selection bias,
and confounder bias) (Supplementary Tables 4 and 5).

3.1. Study Selection Flow. In total, 6414 studies were retrieved from various search engines and databases (Figure 1). After eliminating duplicates, 4882 articles were
selected for critical screening of the titles and abstracts. The
ﬁnal meta-analysis included 153 full-text articles that met
the inclusion criteria. Eighty-six (86) articles were included
in the qualitative synthesis of commonly used herbs by
patients with cancer.

2.6. Data Analysis and Synthesis. The metaprop command in
Stata software (version 12) was used to analyze the data.
Freeman–Tukey double arcsine transformation was used to
“stabilize the raw proportions” [51]. The pooled prevalence
estimates and their conﬁdence intervals (CI) were computed
using the DerSimonian and Laird random-eﬀects model
(DL) and Wald method, respectively, based on “the transformed values and their variances” [51]. We inspected the
forest plots for heterogeneity and then quantiﬁed this using
chi-square tests and the I2 statistic. Because of signiﬁcant
heterogeneity (>50%), we explored the possible modifying
eﬀects of a number of study-level variables on the overall

3.2. Study Characteristics. Characteristics of the included
studies, which involved 809,065 participants (53.95% female) from 44 countries, are given in Table 2. The average
age of the study participants was 50.98 ± 17.39 years, and the
average response rate was 76.95% ± 19.78%. The majority of
studies were conducted in America (34.19%), Europe
(30.32%), and Asia (29.68%). However, based on World
Bank subregions, most studies were carried out in Europe
and Central Asia (32.92%), North America (30.32%), and
East Asia and the Paciﬁc (23.23%). The majority of the
included primary research studies were from high-income
countries (65.77%), with the US at the top of the list of
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Records identiﬁed through database
searching
(n = 5991)

Additional records identiﬁed
through other sources
(n = 423)

Eligibility

Screening

Records after duplicates removed
(n = 4882)

Records screened
(n = 4882)

Full-text articles assessed
for eligibility
(n = 489)

Included

Studies included in
qualitative synthesis
Herbs used (n = 86)

Records excluded
(n = 4393)

Full-text articles excluded,
with reasons
(n = 336)
No speciﬁc data on herbal
medicine use (n = 89)
Conference abstracts (n = 8)
No ethical approval (n = 20)
Letters to editors (n = 2)
Others (qualitative, reviews,
Incomplete data, etc. (n = 217)

Studies included in
quantitative synthesis
(meta-analysis)
(n = 153)

Figure 1: Study selection process based on PRISMA (https://www.prisma-statement.org).

individual countries (27.10%). Most studies used crosssectional designs (99.35%), focused on studying herbal
medicine as part of other CAM modalities (92.26%), and
were conducted in hospital settings (85.81%) among adult
populations (83.23%). Most participants were recruited
using convenience sampling techniques (63.87%). The most
common data collection method was self-administered interviews (52.90%), and the most common cancer type was
breast cancer (18.71%).
3.3. Overall Pooled Prevalence of Herbal Medicine Use in
Cancer by Income and Region. In total, 155 studies reported
crude prevalence estimates of herbal medicine use by patients with cancer [3–40, 55–168]. The prevalence estimates
ranged from 1% (95% CI: 0%-1%) to 93% (95% CI: 92%93%). The overall random-eﬀects pooled prevalence of
herbal medicine use by patients with cancer was 22% (95%
CI: 18%–25%, Figure 2). The I2 statistic was 99.84% (χ2
(df � 154) � 96436.14, P ≤ 0.001), indicating considerable
heterogeneity among the included studies. On inspection,
the funnel plot was symmetrical, as conﬁrmed by Egger’s
regression test (P � 0.063), indicating the absence of smallstudy eﬀects (publication bias).

In terms of continents, the largest pooled prevalence of
herbal medicine use among patients with cancer was found
in Africa (40%, 95% CI: 23%–58%) and Asia (28%, 95% CI:
21%–35%, Figure 2). The lowest prevalence was recorded in
Oceania (9%, 95% CI: 4%–15%). Analysis by subregion
showed the highest prevalence of herbal medicine use
among patients with cancer was in sub-Saharan Africa (40%,
95% CI: 23%–58%), followed by the Middle East (36%, 95%
CI: 19%–54%), Latin America and the Caribbean (35%, 95%
CI: 23%–48%), East Asia and the Paciﬁc (21%, 95% CI: 14%–
29%), North America (20%, 95% CI: 16%–24%), and Europe
and Central Asia (19%, 95% CI: 15%–23%). Among selected
countries (with n ≥ 3 studies), the highest pooled prevalence
of herbal medicine use by patients with cancer was in
Palestine (69%, 95% CI: 59%–77%, n � 4), followed by China
(58%, 95% CI: 45%–71%, n � 7), Turkey (33%, 95% CI: 22%–
44%, n � 18), Taiwan (24%, 95% CI: 9%–42%, n � 7), Canada
(21%, 95% CI: 11%–33%, n � 5), South Korea (21% 95% CI:
7%–40%, n � 3), the US (19%, 95% CI: 15%–24%, n � 42),
mixed European countries (15%, 95% CI: 11%–18%, n � 6),
Germany (12%, 95% CI: 6%–19%, n � 5), Thailand (12%, 95%
CI: 0%–38%, n � 3), Malaysia (10%, 95% CI: 5%–17%, n � 5),
the UK (8%, 95% CI: 3%–14%, n � 9), and Australia (8%,
95% CI: 3%–16%, n � 5). Finally, the pooled prevalence of
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Table 2: Characteristics of included studies (n � 155).
Variable
Female (n � 96)
Age, years (n � 86)
Response rate (n � 99)
Study year (10-year block)
2000–2010
2010–2020
Region (continent)
America
Asia
Europe
Oceania
Africa
Subregion (World Bank category)
Europe and Central Asia
North America
East Asia and Paciﬁc
Middle East
Latin America and the Caribbean
Sub-Saharan Africa
Income (World Bank category)
Low/middle income
High income
Key individual countries (≥5 studies)
USA
Turkey
Taiwan
UK
China
Germany
Malaysia
Australia
Canada
Study design
Cross-sectional/survey
Cohort
Study type/focus
CAM
Herbal medicine only
Study setting
Hospital (e.g., cancer clinic,
institute, center, unit)
Cancer/tumor registry
General population (e.g., online)
Study population
Adults
Children
Both
Sampling method
Convenience
Consecutive
Simple random sampling
Quota
Systematic
Stratiﬁed
Multistage sampling
Data collection methods
Self-report/self-administered
interview

Mean ± standard deviation
or n (%)
53.95 ± 14.04
50.98 ± 17.39
76.95 ± 19.78
80 (51.61)
75 (48.39)
53 (34.19)
46 (29.68)
47 (30.32)
6 (3.87)
3 (1.94)
51 (32.92)
47 (30.32)
36 (23.23)
13 (8.39)
5 (3.23)
3 (1.94)
51 (34.23)
98 (65.77)
42 (27.10)
18 (11.61)
7 (4.52)
9(5.81)
7 (4.52)
5 (3.23)
5 (3.23)
5 (3.23)
5 (3.23)
154 (99.35)
1 (0.65)
143 (92.26)
12 (7.74)
133 (85.81)
6 (3.87)
16 (10.32)
129 (83.23)
23 (14.84)
3 (1.94)
99 (63.87)
38 (24.52)
13 (8.39)
1 (0.65)
1 (0.65)
2 (1.29)
1 (0.65)
82 (52.90)

Table 2: Continued.
Variable
Researcher-administered
interview (telephone, in-person)
Record/document review
Others (mixed, unclear)
Cancer type
Breast
Prostate
Mixed (several types)

Mean ± standard deviation
or n (%)
59 (38.06)
6 (4.11)
8 (5.17)
29 (18.71)
13 (8.39)
113 (72.90)

herbal medicine use in treating cancer was higher among
patients from low- and middle-income countries (32%, 95%
CI: 23%–42%) compared with high-income countries (17%,
95% CI: 14%–21%).
3.4. Overall Subgroup and Meta-Regression Analyses. We
conducted subgroup and meta-regression analyses to investigate the inﬂuence of various patient and study characteristics on the overall observed prevalence estimates to
explore the heterogeneity observed among the included
studies. The subgroup analyses indicated that geographical
region (P ≤ 0.001), subregion (P ≤ 0.001), income group
(P ≤ 0.001), study focus or type (P ≤ 0.001), study country
(P ≤ 0.001), and study design (P ≤ 0.001) had statistically
signiﬁcant moderating eﬀects on the overall pooled prevalence of herbal medicine usage in cancer.
Conversely, in the bivariate meta-regression analysis,
only three variables were related to the overall pooled
prevalence of usage of herbal medicine by cancer patients.
Visual inspection of the scatter plot showed that studies that
investigated herbal medicine in conjunction with other
CAM modalities in cancer (20%, 95% CI: 16–23%) were
more than twice less likely to report a higher pooled
prevalence than studies that focused on herbal medicine use
alone (48%, 95% CI: 35%–61%; β � −1.47, 95% CI: −2.18
to −0.76; P ≤ 0.001; Figure 3(a)). In addition, studies from
high-income countries were less likely to report a high
pooled prevalence of herbal medicine use in cancer compared to those from low- and middle-income countries
(β � −0.803, 95% CI: −1.23 to −0.38; P ≤ 0.001; Figure 3(b)).
However, there was a moderate positive relationship between subregion and pooled prevalence of herbal medicine
use in cancer, with certain subregions being more likely than
others to report a high prevalence of the use of herbal
medicine in cancer (β � 0.134, 95% CI: 0.005–0.264;
P � 0.043).
3.5. Speciﬁc Pooled Prevalence by Study Subpopulation
3.5.1. Pooled Prevalence of Herbal Medicine Use by Children
with Cancer. In total, the crude prevalence estimates of
herbal medicine use by children with cancer was reported by
23 studies [30, 37, 40, 63, 82, 102, 106, 108, 118,
119, 121, 126, 132–135, 137, 143, 146, 151, 157, 165]. The
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Subgroups
Region
Europe
Asia
Africa
America
Oceania
Subregion
Europe and Central asia
East Asia and Paciﬁc
N. America
Sub-Saharan Africa
Middle east
L. America and Carribean
Income
Low/Middle
High income
Country (n ≥ 3 studies)
Palestine
China
Turkey
Taiwan
Canada
South Korea
USA
Germany
Thailand
Malaysia
UK
Australia
Mixed European countries
Study Focus
Herbal medicine Only
CAM
Study design
Cross-sectional
Cohort
Overall

No. of
studies

Prevalence
(95% CI)

47
46
3
53
6

18 (14, 22)
28 (21, 35)
40 (23, 58)
21 (17, 25)
9 (4, 15)

51
36
47
3
13
5

19 (15, 23)
21 (14, 29)
20 (16, 24)
40 (23, 58)
36 (19, 54)
35 (23, 48)

51
98

32 (23, 43)
17 (14, 21)

4
7
18
7
5
3
42
5
3
5
9
5
6

69 (59, 77)
58 (45, 71)
33 (22, 44)
24 (9, 42)
21 (11, 33)
21 (7, 40)
19 (15, 24)
12 (6, 19)
12 (0, 38)
10 (5, 17)
8 (3, 14)
8 (2, 16)
15 (11, 18)

12
143

48 (35, 61)
20 (16, 23)

154
1

22 (18, 25)
42 (38, 46)

155

22 (18, 25)
0

20
40
60
80
100
Prevalence of herbal medicine use (%)

Figure 2: A summary (subgroup) forest plot on herbal medicine usage in cancer.

prevalence estimates ranged from 1% (95% CI: 0%–5%) to
71% (95% CI: 61%–79%). With one exception, these studies
were conducted in America and Europe. The overall random-eﬀects pooled prevalence of herbal medicine use by
children with cancer was 18% (95% CI: 11%–27%; Figure 4).
The I2 statistic was 95.75% (χ2 (df � 22) � 517.11; P ≤ 0.001),
suggesting considerable heterogeneity among the included
studies. Egger’s regression test conﬁrmed that the funnel plot
was asymmetrical (P ≤ 0.001), raising the possibility of
small-study eﬀects (publication bias).
Across income groups, low- and middle-income countries (33%, 95% CI: 16%–52%) were more likely to have a
high prevalence of herbal medicine use by children with
cancer than high-income countries (12%, 95% CI: 7%–18%).
In terms of continents, Europe (18%, 95% CI: 7%–34%) and
America (18%, 95% CI: 10%–28%) had a similar prevalence

of herbal medicine use by children with cancer. Children
with hematological cancers (7%, 95% CI: 2%–16%) were less
likely to report the use of herbal medicine in cancer than
those with all other cancer types combined (20%, 95% CI:
12%–30%).
Subgroup analyses indicated that the income group
(P � 0.02), data collection method (P � 0.01), type of cancer
(P � 0.03), and study period (P � 0.02) had signiﬁcant
moderating eﬀects on the pooled prevalence of the use of
herbal medicine in cancer. However, the meta-regression
analysis showed that only three variables were statistically
signiﬁcant moderators of the pooled prevalence of herbal
medicine usage in cancer. The income group was negatively
related to the pooled prevalence of usage of herbal medicine
in cancer, with studies from high-income countries less
likely to report a high prevalence of the use of herbal
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–4
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CAM
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High

(a)

(b)

Figure 3: Meta-regression of herbal medicine use by study focus (a) and country income level (b), respectively.

Subgroup

Studies (n)

Prevalence (95% CI)

Income
Middle
High

9
14

33.00 (15.00, 52.00)
12.00 (7.00, 18.00)

Region
Europe
America

10
13

18.00 (7.00, 34.00)
18.00 (10.00, 28.00)

Year
2000–2010
2011–2020

12
11

27.00 (16.00, 39.00)
11.00 (4.00, 19.00)

Study type
Self report
Researcher administered

12
11

10.00 (3.00, 20.00)
29.00 (20.00, 39.00)

Cancer type
Heamatological
Mixed

3
20

7.00 (2.00, 16.00)
20.00 (12.00, 30.00)

Overall
Overall sample

23

18.00 (11.00, 27.00)

0
10
20
30
40
Prevalence of herbal medicine use (%)

50

60

Figure 4: A summary (subgroup) forest plot on herbal medicine usage among children with cancer.

medicine by children with cancer than those from low- and
middle-income countries (β � −1.263 95% CI: −2.317395
to −0.208673; P � 0.021). In addition, the use of herbal

medicine was less likely to be reported in studies conducted
between 2011 and 2020 (11%, 95% CI: 4%–19%) than those
conducted between 2000 and 2010 (27%, 95% CI: 16%–39%;
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β � −1.19, 95% CI: −2.22 to −0.15; P � 0.027). However,
studies that used researcher-administered data collection
instruments (29%, 95% CI: 20%–39%) tended to report a
high pooled prevalence of herbal medicine use by children
with cancer than those that were self-administered (10%,
95% CI: 3%–20%; β � 1.38967, 95% CI: 0.418–2.36;
P � 0.007).
3.5.2. Pooled Prevalence of Herbal Medicine Use by Adult
Patients with Cancer. Overall, 130 studies (that met the
eligibility criteria) were incorporated in the meta-analysis of
the prevalence of herbal medicine usage by adult patients
with cancer [3–12, 14–29, 31–36, 38, 39, 55–59, 61,
62, 64–81, 83–101, 103–105, 107, 109–117, 120, 122–125,
127–131, 134, 136, 138–142, 144, 145, 147–150,
152–156, 158–164, 166–168]. The lowest crude prevalence
was 1% (95% CI: 0%–1%) and the highest was 86% (95% CI:
78%–92%).
The random-eﬀects pooled prevalence of the usage of
herbal medicine by adults with cancer was 23% (95% CI:
17%–29%; Figure 5). The I2 statistic was 99.96% (χ2
(df � 129) � 309703.50; P ≤ 0.001), demonstrating considerable heterogeneity among the included studies. The funnel
plot was symmetrical as conﬁrmed by Egger’s regression test
(P � 0.220), suggesting there were no small-study eﬀects
(publication bias).
The highest pooled prevalence of the usage of herbal
medicine in adults with cancer was in Africa (47%, 95% CI:
42%–53%), followed by Asia (30%, 95% CI: 19%–42%),
America (21%, 95% CI: 17%–26%), Europe (18%, 95% CI:
14%–22%), and Oceania (9%, 95% CI: 4%–15%). In terms
of subregions, the highest prevalence of herbal medicine
use among adults with cancer was in sub-Saharan Africa
(47%, 95% CI: 42%–53%), followed by the Middle East
(36%, 95% CI: 15%–60%), East Asia and the Paciﬁc (24%,
95% CI: 13%–37%), North America (21%, 95% CI: 17%–
26%), and Europe and Central Asia (19%, 95% CI: 15%–
23%). Across income groups, adults with cancer from lowand middle-income countries (33%, 95% CI: 22%–44%)
were more likely to report a high prevalence of herbal
medicine than those in high-income countries (19%, 95%
CI: 13%–26%).
The subgroup analyses indicated that study country
(P ≤ 0.001), study focus (P ≤ 0.001), study region (P ≤ 0.001),
study design (P ≤ 0.001), income group (P � 0.02), and
study subregion (P ≤ 0.001) were statistically signiﬁcant
moderators of the pooled prevalence of herbal medicine
usage by adults with cancer. However, bivariate meta-regression revealed that only study focus and income group
had negative relationships with the pooled prevalence.
Studies that focused on herbal medicine along with other
CAM modalities (21%, 95% CI: 15%–27%; β � −1.506, 95%
CI: −2.25 to −0.76; P ≤ 0.001) and those from high-income
countries (β � −0.75, 95% CI: −1.23 to −0.27; P � 0.002) were
less likely to report a high pooled prevalence of herbal
medicine use in adults with cancer than studies that focused
on herbal medicine alone (49%, 95% CI: 34%–64%) and were
from low- and middle-income countries.
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3.6. Speciﬁc Pooled Prevalence by Gender
3.6.1. Pooled Prevalence of Herbal Medicine Use by Male
Patients with Cancer. Twelve studies reported crude prevalence estimates of the use of herbal medicine among male
patients with cancer [71, 76, 88, 90, 97, 101, 112–114,
152, 161, 167]. All of these studies were conducted among
patients with prostate cancer in the Americas and Asia. The
crude prevalence ranged from 1% (95% CI: 0%–7%) to 76%
(95% CI: 75%–76%). The overall random-eﬀects pooled
prevalence of the use of herbal medicine by male patients
with cancer was 17% (95% CI: 1%–47%; Figure 6). The I2
statistic was 99.98% (χ 2 (df � 22) � 44251.66; P ≤ 0.001),
representing signiﬁcant heterogeneity among the included
studies. The funnel plot was symmetrical as conﬁrmed by
Egger’s regression test (P � 0.064), indicating the absence of
small-study eﬀects (publication bias).
The continent of Asia (23%, 95% CI: 0%–80%) had a
higher prevalence of the male patients with cancer who used
herbal medicine compared with America (13%, 95% CI: 8%–
20%). Subgroup analyses indicated that only the study period (P ≤ 0.001) had a statistically signiﬁcant moderating
eﬀect on the overall pooled prevalence of the use of herbal
medicine among male patients with cancer. Contrariwise,
the meta-regression analysis showed that this relationship
was weak, with studies conducted between 2011 and 2020
(74%, 95% CI: 74%–75%) more likely to report a high
prevalence of the use of herbal medicine by male patients
with cancer than those conducted between 2000 and 2010
(11%, 95% CI: 7%–16%; β � 2.06, 95% CI: −0.002 to 4.13;
P � 0.050).

3.6.2. Pooled Prevalence of Herbal Medicine Use by Female
Patients with Cancer. The prevalence of herbal medicine
usage in female patients with cancer was reported in 35
studies [9, 10, 18, 24, 27, 28, 38, 55, 61, 64, 73, 83–85,
87, 90, 93, 95, 100, 110, 115, 123, 125, 138, 141, 145, 147,
149, 154, 155, 159, 163, 164, 166, 168]. With one exception,
these studies were conducted in Asia, America, and Europe.
The lowest prevalence of female patients with cancer using
herbal medicine was 3% (95% CI: 2%–5%) and the highest
was 85% (95% CI: 82%–87%). The random-eﬀects pooled
prevalence of the usage of herbal medicine by female patients
with cancer was 27% (95% CI: 19%–35%; Figure 7). The I2
statistic was 99.63% (χ2 (df � 34) � 9133.34; P ≤ 0.001)
reﬂecting considerable heterogeneity among the included
studies. The funnel plot was symmetrical as conﬁrmed by
Egger’s regression test (P � 0.967P � 0.967), indicating the
absence of small-study eﬀects (publication bias).
Among continents, the highest prevalence of the use of
herbal medicine by female cancer patients was in Asia (31%,
95% CI: 16%–48%) followed by America (27%, 95% CI:
19%–36%) and Europe (22%, 95% CI: 11%–37%). The
Middle East subregion (31%, 95% CI: 4%–69%) had the
highest prevalence of the use of herbal medicine by female
patients with cancer, followed by North America (27%, 95%
CI: 19%–36%), East Asia and the Paciﬁc (26%, 95% CI: 10%–
48%), and Europe and Central Asia (25%, 95% CI: 14%–
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Subgroup

Studies (n)

Prevalence (95% CI)

Region
Europe
Asia
Africa
America
Oceania

37
44
2
41
6

18.00 (14.00, 22.00)
30.00 (19.00, 42.00)
47.00 (42.00, 53.00)
21.00 (17.00, 26.00)
91.00 (4.00, 15.00)

Subregion
Europe and central asia
East asia and paciﬁc
N.America
Sub-Saharan africa
Middle east
L. America and carribean

42
35
39
2
11
1

19.00 (15.00, 23.00)
24.00 (13.00, 37.00)
21.00 (17.00, 26.00)
47.00 (42.00, 53.00)
36.00 (15.00, 60.00)
37.00 (32.00, 42.00)

Income
Middle
High income

40
84

33.00 (22.00, 44.00)
19.00 (13.00, 26.00)

Study focus
Herbal medicine only
CAM

11
119

49.00 (34.00, 64.00)
21.00 (15.00, 27.00)

Study design
Cross-sectional
Cohort

129
1

23.00 (17.00, 29.00)
42.00 (38.00, 46.00)

Overall sample
Overall

130

23.00 (17.00, 29.00)

0 10 20 30 40 50 60 70
Prevalence of herbal medicine use (%)

Figure 5: A summary (subgroup) forest plot on herbal medicine usage among adult patients with cancer.

37%). A higher pooled prevalence of herbal medicine usage
among female patients was recorded in low- and middleincome countries (34%, 95% CI: 14%–58%) compared with
high-income countries (24%, 95% CI: 18%–30%). Similarly,
studies involving patients with other cancers combined
(28%, 95% CI: 14%–44%) tended to report a higher prevalence of herbal medicine usage among female patients with
cancer than studies that focused on breast cancer alone
(26%, 95% CI: 18%–36%).
The subgroup analysis showed that the study focus
(P ≤ 0.001) and study region (P ≤ 0.001) had a statistically
signiﬁcant moderating eﬀect on the overall pooled prevalence of the use of herbal medicine among female patients
with cancer. However, in the meta-regression analysis, only
study focus had a weak negative relationship with the pooled
prevalence of herbal medicine use in cancer. Studies that
focused on herbal medicine along with other CAM modalities (25%, 95% CI: 17%–33%; β � −1.634, 95% CI:
−3.49–0.220; P � 0.082; Figure 7) were less likely to have a

high pooled prevalence than studies that focused on herbal
medicine use in cancer alone (63%, 95% CI: 55%–71%).
3.7. Herbs Used and Reported by Patients with Cancer. In
total, 86 studies reported herbs most commonly used in
cancer, which included the following: evening primrose
(Oenothera biennis), Echinacea (Echinacea purpurea), garlic
(Allium sativum), stinging nettle (Urtica dioica), garden
thyme (Thymus vulgaris), black cumin (Nigella sativa), green
tea (Camellia sinensis), ginseng (Panax ginseng), ginger
(Zingiber oﬃcinale), ﬂaxseed (Linum usitatissimum), myrtle
(Myrtus communis), ginkgo (Ginkgo biloba), aloe vera (Aloe
barbadensis), St. John’s wort (Hypericum perforatum), Essiac
(containing four herbs: sorrel, slippery elm, Turkey rhubarb,
and burdock), garden sage (Salvia oﬃcinalis), rosehip (Rosa
canina), rosemary (Rosmarinus oﬃcinalis), turmeric (Curcuma longa), peppermint (Mentha piperita), Sabah snake
grass (Clinacanthus nutans), kava kava (Piper methysticum),
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Studies (n)

Prevalence (95% CI)
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America

8

13.00 (8.00, 20.00)

Asia
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23.00 (0.00, 80.00)
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2000–2010
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11.00 (7.00, 16.00)

2011–2020

2

74.00 (74.00, 75.00)

12

17.00 (1.00, 47.00)

Overall sample
Overall

0
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Prevalence of herbal medicine use (%)

90

Figure 6: A summary (subgroup) forest plot on herbal medicine usage among male patients with cancer.

Subgroup
Region
Europe
Asia
America
Subregion
Europe and central asia
East asia and paciﬁc
Middle east
North america
Income
Middle
High
Study focus
Herbal medicine only
CAM
Cancer type∗
Breast
Mixed
Overall

Studies (n)

Prevalence (95% CI)

7
14
13

22 (11, 37)
31 (16, 48)
27 (19, 36)

10
9
3
13

25 (14, 37)
26 (10, 48)
31 (4, 69)
27 (19, 36)

11
22

34 (14, 58)
24 (18, 30)

2
33

63 (55, 71)
25 (17, 23)

29
6

26 (18, 36)
28 (14, 44)

35

27 (19, 35)
0
20
40
60
Prevalence of herbal medicine use (%)

Figure 7: A summary (subgroup) forest plot on herbal medicine usage among female patients with cancer.

chamomile (Matricaria chamomilla), mistletoe (Viscum
album), soy products (Glycine max), wild Hedyotis diﬀusa,
barbed skullcap (Scutellaria barbata), noni (Morinda citrifolia), grape seed extract (Vitis vinifera), grapefruit (Citrus
paradisi), milk thistle (Silybum marianum), French lavender

(Lavendula stoechas), senna (Cassia acutifolia), licorice root
(Glycyrrhiza glabra), cinnamon (Cinnamonum zeylanicum),
snakehead (Chana striata), blackberry (Rubus caesius), saw
palmetto (Serenoa repens), and wormwood (Artemisia
absinthium). Other herbs that were less commonly used but
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reported by patients with cancer are listed in Supplementary
Table 6.

4. Discussion
It has become increasingly common to base healthcare
decision-making on information obtained from evidencebased medicine. Previously, this information was obtained
from systematic reviews of interventional studies. However,
this evidence is now also being acquired from systematic
reviews of observational studies. The present review investigated the prevalence of the herbal medicine use among
patients with cancer to inform and guide the development of
healthcare policies concerning integrating herbal medicine
in clinical cancer care.
This review suggested that a large estimated percentage
of cancer patients use herbal medicine, especially during
conventional treatment. The overall pooled prevalence of
herbal medicine usage by patients with cancer was 22% (95%
CI: 18%–25%), which means approximately one in ﬁve
patients with cancer used herbal medicine(s) following a
cancer diagnosis. This ﬁnding was consistent with the literature, where herbal medicine was reported as the leading
form of CAM used in cancer [4–6, 8, 11, 12, 114]. This review
also found that Africa and Asia had the highest pooled
prevalence of the usage herbal medicine in cancer, with the
lowest prevalence recorded in Oceania. Similarly, a larger
percentage of patients with cancer from low- and middleincome countries used herbal medicine compared with those
from high-income countries. This trend was repeated across
speciﬁc subpopulations of children, adults, and female patients with cancer. The variation in prevalence across regions
may be explained by variances in geographical characteristics (i.e., conditions that make some herbs easily available),
cultural beliefs and attitudes, and liberalized or low regulation of herbal medicines [18–20, 31, 79, 131, 139, 162].
Conversely, the high herbal medicine usage in low- and
middle-income countries might possibly be because of the
low income levels, which may mean that patients with cancer
are unable to pay for conventional cancer care (ﬁnancial
constraints) and or due to deeply rooted cultural practices
related or favorable to use of herbal medicines. For example,
as shown in this study, Asian countries such as South Korea
and Taiwan, despite having the conditions and economic
power to receive high-quality conventional therapies, patients from these countries still continue to use herbal
medicine while accepting conventional therapies. Above all,
high-income countries (of North America and Europe)
where most studies included in this review were conducted
do not possess a specialized or deeply ingrained traditional
medicine use culture compared to countries of Asia and
Africa.
The ﬁndings of this review suggested that compared to
children (with cancer), adult patients with cancer were more
likely to use herbal medicine, although this diﬀerence was
not statistically signiﬁcant. This variance in prevalence may
be related to adults having more freedom to use herbal
medicine than children who generally depend on their
parents to access such products [106]. However, given the
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physiological nature of children (i.e., immaturity of organs
such as the liver) and the potential risks of herbal medicine
for children as reported in previous studies, parents need to
make informed decisions based on evidence-based information before administering herbal medicine to their
children to protect children from possible harmful eﬀects
[37].
We also found that more female patients with cancer
compared to their male counterparts used herbal medicine.
However, the pooled prevalence of the use of herbal medicine by male patients with cancer was from studies conducted among patients with prostate cancer; therefore, that
reported prevalence best represents herbal medicine usage
among patients with prostate cancer. Similarly, most studies
that focused on female patients with cancer included patients with breast cancer, although the use of herbal medicine was higher in breast cancer than prostate cancer. These
gender-based ﬁndings concur with previous literature,
where the use of herbal medicine in cancer was related to
being female, with women more likely to use herbal medicine as a primary mode of healthcare than men [22, 23, 138].
Finally, this review revealed several herbs commonly
used in cancer, some with proven evidence of beneﬁcial
eﬀects (anticancer eﬀects) and others with potential risks
(harmful side eﬀects and drug interactions) to patients.
Those with possible detrimental eﬀects to patients included
garlic, ginseng, kava, and St. John’s wort [31, 32, 35]. Given
that most of the studies that reported use of those herbs were
conducted among cancer patients who were receiving
conventional cancer therapies, clinicians (oncologists)
should ask about herbal medicine use during their routine
care of such patients.
4.1. Implications and Recommendations. Regardless of variation in the level of herbal medicine regulatory frameworks
in diﬀerent countries across the world, the high percentage
of the usage of herbal medicine reported by this study calls
for some form of integration of herbal medicine into cancer
care. Healthcare providers must be at the center of this
integration. The lack of suﬃcient clinical evidence should
not be a deterrent to this integration, although health
practitioners at all levels of patient care should routinely ask
about, oﬀer, and document evidence-based advice to patients with cancer on the safety and possible beneﬁts of herbs
and herb-drug interactions. Routine discussion of these
issues during cancer screening, treatment, and follow-up
may help to improve patient care outcomes. However, to
equip health workers with evolving evidence on herbal
medicines used in cancer, health educators need to continue
incorporating knowledge about herbal medicines in oncological care training curricula and also develop programs
geared toward understanding, evaluating, and validating
herbal medicine use in cancer. In the short-term, health
managers could develop short courses or refresher training
for in-service healthcare workers on herbal medicines used
in cancer to improve their knowledge on this subject.
In addition, policy makers at national governmental and
international levels, such as drug authorities and health

12
ministries, should incorporate and update new evidence
regarding herbal medicine into oncology treatment guidelines, standard operating procedures, patient charts or
electronic medical records, and pharmacopeias. This will
assist healthcare workers to document herbal medicine
practices in clinical care, which will subsequently promote
clinical research on herbal medicine use in cancer.
As evidence regarding herbal medicine continues to
evolve, policy makers in countries that regulate herbal
medicine as dietary supplements or do not regulate herbal
medicine at all need to update, review, or change their herbal
medicine regulatory frameworks (either entirely or on a
case-by-case basis) to protect patients with cancer from
possible harmful eﬀects posed by some herbs. In addition, as
the media and other informal sources of information on
herbal medicine are responsible for the high use of herbal
medicine by cancer patients, oncology care centers and
policy makers could create oﬃcial websites or other media
platforms with authentic and updated information on
commonly or locally available herbal medicines to counter
the misinformation from other sources. These platforms
may be communicated to patients during routine cancer
care. Importantly, these platforms should encourage patients
to always seek advice regarding their speciﬁc circumstances
from a qualiﬁed healthcare professional.
Successful integration of herbal medicine into cancer
care either as an alternative form of medicine or alongside
cancer medicine requires further high-quality multidisciplinary research on herbal medicines used in cancer, which
requires research funding. Therefore, policy makers need to
advocate, fundraise, and allocate resources for cancer research concerning herbal medicine use. For example, the
lack of funding for research on herbal medicines may explain
the relatively few published studies on herbal medicine in
cancer, especially in Africa and South America, as observed
in this study. In addition, it is important to note that in this
study, we were unable to conduct a meta-analysis of the
usage of herbal medicine in cancer across many other patients’ characteristics due to inconsistent study variables.
Therefore, it is necessary to develop a standardized survey
tool customizable to various patients with cancer and settings to measure herbal medicine use in cancer. Such a tool
will allow comprehensive systematic reviews to be conducted on this subject. It is also necessary to conduct more
herbal medicine-speciﬁc observational research in cancer to
obtain extensive statistics on the extent of herbal medicine
usage in cancer across the world.
4.2. Limitations and Strengths of This Study. In terms of the
quality of included studies, we rated the majority of studies
as having a moderate to high risk of bias, which might have
led to over- or underestimation of the pooled prevalence of
herbal medicine use reported in this study. This was expected
given that nearly all studies used cross-sectional designs.
However, the majority of the included studies had moderately large sample sizes and high response rates. Second,
there was a high proportion of heterogeneity (between-study
heterogeneity) associated with the estimated pooled
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prevalence(s) reported in this study. However, this was
minimized through estimating the pooled prevalence using a
random-eﬀects model and performing extensive subgroup
and meta-regression analyses. Third, we acknowledge the
limited number of studies from sub-Saharan Africa, and the
pooled estimate from the few available studies might be
overestimated. However, this provides an opportunity for
further research on usage of herbal medicine among patients
with cancer in Africa. Fourth, we only included studies
published in the English language (thus missing studies
published in other languages, particularly from the Francophone or Portuguese speaking countries) and did not
include grey literature (dissertations or conference abstracts), which might have aﬀected the outcomes (pooled
prevalence rates) reported. Nonetheless, based on examination of the funnel plots and use of Egger’s test of funnel
plot asymmetry, no evidence of small-study eﬀects (publication bias) was observed (found) across a sample of primary
studies included in this study; therefore, the results of this
review are unlikely to reﬂect bias. The majority of the included primary studies were prospective, and suﬃcient time
was invested in these studies, making their results somewhat
reliable. Finally, this study provides a strong point of reference for future studies, as it is one of the ﬁrst reviews to be
conducted on the prevalence of the use of herbal medicine
amongst cancer patients.

5. Conclusion
This systematic review shows that a large percentage of
patients with cancer use herbal medicine, especially those
from low- and middle-income countries. In addition, larger
percentages of adult patients with cancer (compared with
children) and female patients with cancer (compared with
males) used herbal medicine. In summary, there is need for
additional epidemiological investigations exploring herbal
medicine integration into cancer care especially for low- and
middle-income countries.
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